Title:
【発明の名称】平滑筋弛緩活性および/またはマスト細胞安定化活性および/または抗炎症活性を有するインダン化合物
Document Type and Number:
Japanese Patent JP2000506497
Kind Code:
A
Abstract:
Indane compounds of general formulas (7) and (8) and their pharmaceutical use particularly to achieve smooth muscle relaxing activity and/or mast cell stabilizing activity and/or anti-inflammatory activity as described, wherein in formula (7) R2 to R13, in formula (8) R1 and R3 and R13 are selected from one or more of the same or different of: H, halo, hydroxy, alkoxy, aryloxy, acetoxy, carboxy, alkyl carbonyl, hydro carbonyl, amino, amido, alkylamino, hydroxylamino, amine oxide groups, azo groups, cyano, hydrazino groups, hydrazide groups, hydrazone groups, imide groups, iminoether groups, ureyl groups, oxime, nitro, nitrate, nitrite, nitroso groups, nitrile, heterocyclic groups containing heretro atoms containing one or more of N, O or S, aralkyl groups, mono and polybenzoid aryl groups, substituted aryl groups, thiol, thioureyl, phenylthiol groups, sulphonic acid groups, sulphoxide groups, sulphone groups, alkyl containing 1 to 10 carbon atoms or cycloalkyl groups containing 3 to 8 carbon atoms which may saturated or unsaturated, substituted alkyl or cycloalkyl groups which may be saturated or unsaturated. X is a bond, O, or NR (wherein R is acyl, alkyl or sulphonate groups), S, SO or SO2, when X is a bond any of R8 and R13; R8 and R12; R8 and R9 may together represent a double bond, in formula (7) any one or more of R2, 1R2 R3, 1R3; R9, 1R9; R10, 1R10; R11, 1R11; R12, 1R12 may together represent oxo, and in formula (8) any one or more of R1, 1R1, R3, 1R3; R9, 1R9; R10, 1R10; R11, 1R11; R12; 1R12 may together represent oxo.
Inventors:
Walsh, John
Frankish, Nail
Sheridan, Helen
Byrne, william
Frankish, Nail
Sheridan, Helen
Byrne, william
Application Number:
JP52112797A
Publication Date:
May 30, 2000
Filing Date:
December 06, 1996
Export Citation:
Assignee:
Venan Tias Limited
International Classes:
A61K31/00; A61K31/015; A61K31/12; A61K31/13; A61K31/135; A61K31/136; A61K31/15; A61K31/16; A61K31/165; A61K31/167; A61K31/18; A61K31/185; A61K31/19; A61K31/21; A61K31/215; A61K31/235; A61K31/045; A61K31/27; A61K31/275; A61K31/33; A61P9/00; A61P9/12; A61P11/00; A61P11/06; A61P11/08; A61P29/00; A61P37/00; A61P37/08; C07C1/207; C07C13/465; C07C29/143; C07C35/32; C07C35/52; C07C41/09; C07C43/188; C07C43/235; C07C45/46; C07C45/51; C07C45/61; C07C45/62; C07C45/65; C07C45/67; C07C45/68; C07C45/71; C07C45/74; C07C49/653; C07C49/665; C07C49/67; C07C49/683; C07C49/697; C07C49/755; C07C59/86; C07C62/38; C07C65/36; C07C65/38; C07C69/007; C07C69/013; C07C69/157; C07C69/716; C07C69/738; C07C69/757; C07C69/76; C07C69/92; C07C215/44; C07C221/00; C07C225/20; C07C231/02; C07C233/32; C07C233/33; C07C249/08; C07C251/36; C07C251/44; C07C269/02; C07C271/38; C07C303/28; C07C309/66; C07C311/20; C07D317/72; (IPC1-7): C07C49/653; A61P11/08; A61P29/00; A61P37/00; A61K31/045; A61K31/12; A61K31/13; A61K31/16; A61K31/19; C07C35/32; C07C49/755; C07C69/157; C07C221/00; C07C225/20; C07C233/32; C07C311/20
Attorney, Agent or Firm:
Akihiko Umeda